Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026

Biodesix announced multiple presentations at CHEST 2026 showcasing real-world evidence for integrating Nodify Lung blood-based testing into routine lung nodule management. The presentations include sponsored research comparing biomarkers with PET imaging, independent studies on patient follow-up adherence, and analyses from the CLARIFY study involving over 2,000 patients. The company is demonstrating how blood-based biomarkers can be incorporated into structured care pathways alongside imaging.